Symphogen’s strategic priority is to commercialize our powerful research, preclinical and early development platform with the aim of establishing Symphogen as a preferred partner for the discovery and development of highly differentiated antibody therapeutics, either as combination or stand-alone therapies.As an affiliate of Servier our strategic focus is to apply our highly effective antibody platform and capabilities in th...
Symphogen’s strategic priority is to commercialize our powerful research, preclinical and early development platform with the aim of establishing Symphogen as a preferred partner for the discovery and development of highly differentiated antibody therapeutics, either as combination or stand-alone therapies.As an affiliate of Servier our strategic focus is to apply our highly effective antibody platform and capabilities in the discovery and early development of highly differentiated antibody therapeutics, either as combination or stand-alone therapies supporting Servier’s R&D strategy.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.